1. Home
  2. JBTM vs DVA Comparison

JBTM vs DVA Comparison

Compare JBTM & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JBT Marel Corporation

JBTM

JBT Marel Corporation

HOLD

Current Price

$159.03

Market Cap

8.1B

Sector

N/A

ML Signal

HOLD

Logo DaVita Inc.

DVA

DaVita Inc.

HOLD

Current Price

$104.90

Market Cap

8.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBTM
DVA
Founded
1994
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
8.2B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
JBTM
DVA
Price
$159.03
$104.90
Analyst Decision
Strong Buy
Hold
Analyst Count
3
4
Target Price
$161.50
$145.00
AVG Volume (30 Days)
458.8K
799.0K
Earning Date
02-23-2026
02-12-2026
Dividend Yield
0.25%
N/A
EPS Growth
N/A
5.63
EPS
N/A
9.76
Revenue
$3,257,800,000.00
$13,317,965,000.00
Revenue This Year
$124.13
$6.50
Revenue Next Year
$4.45
$2.97
P/E Ratio
N/A
$10.73
Revenue Growth
92.43
5.14
52 Week Low
$90.08
$101.00
52 Week High
$160.84
$179.60

Technical Indicators

Market Signals
Indicator
JBTM
DVA
Relative Strength Index (RSI) 63.46 29.58
Support Level $154.58 $101.00
Resistance Level $160.40 $106.38
Average True Range (ATR) 3.67 3.05
MACD -0.15 -0.77
Stochastic Oscillator 84.65 26.82

Price Performance

Historical Comparison
JBTM
DVA

About JBTM JBT Marel Corporation

JBT Marel Corp is a technology solutions provider to segments of the food and beverage industry. It designs, produces, and services products and systems for a broad range of end markets, generating roughly one-half of annual revenue from recurring parts, services, rebuilds, and leasing operations.

About DVA DaVita Inc.

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.

Share on Social Networks: